Viridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call Transcript

SA Transcripts
153.96K Followers

Q3: 2022-11-14 Earnings Summary

EPS of -$0.86 beats by $0.15
 | Revenue of $1.20M (474.52% Y/Y) beats by $935.00K

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET

Company Participants

John Jordan - Vice President of Investor Relations
Jonathan Violin - President & Chief Executive Officer
Barrett Katz - Chief Medical Officer
Kristian Humer - Chief Financial Officer & Chief Business Officer

Conference Call Participants

Rami Katkhuda - LifeSci Capital
Gavin Clark-Gartner - Evercore ISI
Thomas Smith - SVB Securities
Laura Chico - Wedbush Securities
Kalpit Patel - B. Riley Securities
Jason Butler - JMP Securities

Operator

Greetings and welcome to Viridian Therapeutics Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, John Jordan, Vice President of Investor Relations. Please, go ahead.

John Jordan

Thank you, Brock. Good morning, everyone, and welcome to the Viridian conference call to discuss the positive clinical data report earlier today for VRDN-001 in patients with Thyroid Eye Disease.

Before we begin, I'd like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and 10-Q and other reports on file with the SEC.

I'm joined today by Dr. Jonathan

Recommended For You

About VRDN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on VRDN